Company profile
Domain Therapeutics
#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation
- Industry
- Pharmaceutical Manufacturing
- Employees
- 36
- Headquarters
- Illkirch-Graffenstaden, Grand Est
- Founded
- 2008
- LinkedIn followers
- 10,385
- Office locations
- 2
Domain Therapeutics company summary
Domain Therapeutics is a company in the Pharmaceutical Manufacturing industry, headquartered in Illkirch-Graffenstaden, Grand Est, founded in 2008. On LinkedIn the company has around 36 employees and 10,385 followers. The company lists 2 office locations. Its listed specialties include GPCR, immuno-oncology, cancer, immunotherapy, clinical research.
What technology does Domain Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Domain Therapeutics
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
Specialties
Where is Domain Therapeutics located?
Domain Therapeutics lists 2 office locations.
Compare companies similar to Domain Therapeutics
More companies in Pharmaceutical Manufacturing.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Domain Therapeutics domaintherapeutics.com | Pharmaceutical Manufacturing | 36 | 2008 | Illkirch-Graffenstaden, Grand Est |
 Anacor Pharmaceuticals pfizer.com | Pharmaceutical Manufacturing | 108,102 | - | New York, New York |
 Sanofi sanofi.com | Pharmaceutical Manufacturing | 93,352 | - | Paris, France, FR |
 GSK gsk.com | Pharmaceutical Manufacturing | 92,179 | - | London, England |
 Novartis España novartis.com | Pharmaceutical Manufacturing | 85,373 | - | Basel, Baselstadt |
 AstraZeneca astrazeneca.com | Pharmaceutical Manufacturing | 80,667 | - | Cambridge, Cambridgeshire, GB |
 Eli Lilly and Company lilly.com | Pharmaceutical Manufacturing | 57,202 | - | Indianapolis, Indiana |
 Merck merck.us | Pharmaceutical Manufacturing | 44,794 | - | Rahway, New Jersey |
 SUN PHARMA sunpharma.com | Pharmaceutical Manufacturing | 47,764 | 1983 | Mumbai, Maharastra |
 Boehringer Ingelheim boehringer-ingelheim.com | Pharmaceutical Manufacturing | 47,150 | - | Ingelheim am Rhein, Rhineland-Palatinate |
 Cipla cipla.com | Pharmaceutical Manufacturing | 51,911 | - | Mumbai, Maharashtra |
Frequently asked questions about Domain Therapeutics
What does Domain Therapeutics do?
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.
How many employees does Domain Therapeutics have?
Domain Therapeutics has around 36 employees on LinkedIn.
Where is Domain Therapeutics headquartered?
Domain Therapeutics is headquartered in Illkirch-Graffenstaden, Grand Est.
Where does Domain Therapeutics have offices?
Domain Therapeutics lists 2 office locations, including Illkirch-Graffenstaden, Grand Est, FR; Montreal, Quebec H4S 1Z9, CA.
When was Domain Therapeutics founded?
Domain Therapeutics was founded in 2008.
Build a lead list from companies like Domain Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.